Consolidated Statement of Stockholders' Equity (unaudited) - 9 months ended Jun. 30, 2017 - USD ($)	Total	Amgen	Preferred Stock	Common Stock	Common Stock Amgen	Additional Paid-In Capital	Additional Paid-In Capital Amgen	Accumulated Other Comprehensive Income (loss)	Accumulated Deficit	Non-controlling Interest
Beginning Balance, Amount at Sep. 30, 2016	$ 95,024,259		$ 16	$ 162,116		$ 493,844,909		$ 7,449	$ (398,435,043)	$ (555,188)
Beginning Balance, Shares at Sep. 30, 2016			15,652	69,746,685
Stock-based compensation	5,881,901					5,881,901
Exercise of stock options, Amount	$ 271,931			$ 136		271,795
Exercise of stock options, Shares	135,730			135,730
Common stock- Restricted Stock Units vesting, Amount	$ (381,563)			$ 473		(382,036)
Common stock- Restricted Stock Units vesting, Shares				472,889
Stock issuances		$ 12,420,000			$ 1,746		$ 12,418,254
Stock issuances, Shares					1,745,810
Preferred stock converted to common stock, Amount			$ (16)	$ 2,671		(2,655)
Preferred stock converted to common stock, Shares			(15,652)	2,670,989
Foreign currency translation adjustments	(25,835)							(25,835)
Net loss	(23,648,409)								(23,648,409)
Ending Balance, Amount at Jun. 30, 2017	$ 89,542,284			$ 167,142		$ 512,032,168		$ (18,386)	$ (422,083,452)	$ (555,188)
Ending Balance, Shares at Jun. 30, 2017				74,772,103